IntroductionThe prevalence of diabetes mellitus is rising at an exponential rateglobally, with type 2 diabetes mellitus (T2DM) the most commonform. The presence of coronary artery disease in patients withT2DM results in significant mortality and morbidity. The relativerisk of cardiovascular events in those with T2DM remainsunchanged despite good management of the diabetes mellitusand other cardiovascular risk factors. Recurrent cardiovascularthrombotic events are more common in coronary artery diseasepatients who have T2DM than in those without T2DM, despitecurrent ‘gold standard’ secondary prevention therapy.1 Bloodthrombogenicity (the ability of blood to clot or ‘blood vulnerability’)is greater in T2DM patients and is associated with pooreroutcomes. Better understanding and identification of noveltherapeutic targets that can be used to reduce thrombogenicitymight improve clinical outcomes in this high-risk population.
展开▼
